同源重组缺陷肿瘤中联合放化疗的合成细胞毒性增加
该研究采用同源与非同源乳腺癌细胞系及一项新辅助放化疗二期临床试验的4例三阴性乳腺癌全基因组测序,评估同源重组缺陷(HRD)对顺铂联合放疗(c-RT)敏感性的影响。结果显示BRCA1/2缺陷及高基因组瘢痕评分的HRD肿瘤对c-RT表现出合成细胞毒性,1例达到病理完全缓解的患者具有HRD特征。作者认为HRD乳腺癌可能对c-RT高度敏感,值得进一步临床研究以指导精准肿瘤学方法。
要点
- BRCA1/2缺陷细胞系在2 μM顺铂和6 Gy条件下c-RT与单药交互比分别为1.11和26.84。
- 高LST评分细胞系在2 Gy和20 μM顺铂下交互比为7.50,低LST细胞系为0.65。
- 二期试验4例可评估患者中1例达到病理完全缓解并具有HRD特征。
核心结论
- HRD乳腺癌无论通过BRCA1/2突变状态、功能试验还是突变特征识别,似乎比同源对照或无HRD突变特征的肿瘤对c-RT显著更敏感。
- HRD肿瘤可能对c-RT高度敏感,值得进一步临床研究以指导精准肿瘤学方法。
研究设计与样本
- 研究使用同源和非同源乳腺癌细胞系检测c-RT敏感性。
- HRD通过4种试验评估:放疗诱导的Rad51焦点、DR-GFP报告试验、基因组瘢痕评分(大规模状态转换[LST])和克隆生存试验。
- 对一项三阴性乳腺癌新辅助c-RT二期临床试验的4例乳腺肿瘤进行全基因组测序,并使用HRDetect定义HRD。
主要发现
- BRCA1/2缺陷细胞系基于Rad51功能试验显示功能性HRD,BRCA1同源对在2 μM顺铂和6 Gy条件下c-RT与放疗或顺铂的交互比分别为1.11和26.84。
- 最高LST细胞系显示HRD并对c-RT有合成细胞毒性,在2 Gy和20 μM顺铂下交互比为7.50,最低LST细胞系交互比为0.65。
- 二期试验4例可评估患者中,1例达到病理完全缓解,并基于包括HRDetect和LST评分在内的多种基因组瘢痕评分具有相应HRD,与未达到病理完全缓解的患者相比。
局限性
- HRD肿瘤可能对c-RT高度敏感,值得进一步临床研究以指导精准肿瘤学方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Homologous recombination deficient (HRD) tumors are exquisitely sensitive to platinum-based chemotherapy and when combined with radiation therapy (RT), leads to improved overall survival in multiple cancer types. Whether a subset of tumors with distinct molecular characteristics demonstrate increased benefit from cisplatin and RT (c-RT) is unclear. We hypothesized that HRD tumors, whether associated with BRCA mutations or genomic scars of HRD, exhibit exquisite sensitivity to c-RT, and that HRD may be a significant driver of c-RT benefit. METHODS AND MATERIALS: Sensitivity to c-RT was examined using isogenic and sporadic breast cancer cell lines. HRD was assessed using 4 assays: RT-induced Rad51 foci, a DR-GFP reporter assay, a genomic scar score (large-scale state transitions [LST]), and clonogenic survival assays. Whole-genome sequencing of 4 breast tumors from a phase 2 clinical trial of neoadjuvant c-RT in triple-negative breast cancer was performed and HRD was defined using HRDetect. RESULTS: BRCA1/2 deficient cell lines displayed functional HRD based on the Rad51 functional assay, with c-RT to RT or cisplatin interaction ratios (IR) of 1.11 and 26.84 for the BRCA1 isogenic pair at 2 μM cisplatin and 6 Gy, respectively. The highest LST lines demonstrated HRD and synthetic cytotoxicity to c-RT with IR at 2 Gy and cisplatin 20 μM of 7.50, and the lowest LST line with IR of 0.65. Of 4 evaluable patients in the phase 2 trial, one achieved a pathologic complete response with corresponding HRD based on multiple genomic scar scores including HRDetect and LST scores, compared with patients without a pathologic complete response. CONCLUSIONS: HRD breast cancers, whether identified by BRCA1/2 mutation status, functional tests, or mutational signatures, appear to be significantly more sensitive to c-RT compared with isogenic controls or tumors without HRD mutational signatures. HRD tumors may be exquisitely sensitive to c-RT which warrants further clinical investigation to guide a precision oncology approach.
引用
- Ma J, Shah R, Bell AC, et al. Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors. Int J Radiat Oncol Biol Phys. 2024. PMID: 38997095. doi:10.1016/j.ijrobp.2024.06.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。